• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Levy Hadar was granted 59,595 units of Ordinary Shares

    9/19/23 4:38:02 PM ET
    $RWLK
    Industrial Specialties
    Health Care
    Get the next $RWLK alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Levy Hadar

    (Last) (First) (Middle)
    C/O REWALK ROBOTICS LTD.
    3 HATNUFA ST., P.O. BOX 161

    (Street)
    YOKNEAM ILIT L3 L3 20692203

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ReWalk Robotics Ltd. [ RWLK ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/13/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares, par value NIS 0.25 per share 09/13/2023 A 59,595(1) A $0.00 109,595 I ESOP
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents 59,595 ordinary shares, par value NIS 0.25 per share, issuable upon the vesting of restricted stock units ("RSUs") granted on September 13, 2023 (the "Grant Date") under the ReWalk Robotics Ltd. Amended and Restated 2014 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months following the Grant Date.
    /s/ Hadar Levy 09/19/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RWLK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RWLK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RWLK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lind Global Fund Ii Lp bought $40,089 worth of Ordinary Shares (54,917 units at $0.73) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      11/21/23 4:37:18 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • Lind Global Fund Ii Lp bought $49,516 worth of Ordinary Shares (72,818 units at $0.68) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      11/16/23 4:37:44 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • Lind Global Fund Ii Lp sold $3,521,840 worth of Ordinary Shares (5,031,200 units at $0.70) and bought $3,521,840 worth of Ordinary Shares (5,031,200 units at $0.70) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      9/28/23 4:30:24 PM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • VA STAND Act introduced in the United States Senate

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today applauded the introduction of a Senate companion bill to H.R. 6373, the VA Spinal Trauma Access to New Devices (STAND) Act. The Senate companion bill was introduced by Chairman of the Senate Veterans' Affairs Committee, Senator Jon Tester (D-MT), and the Ranking Member of that committee, Senator Jerry Moran (R-KS).

      3/22/24 8:30:00 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care
    • Lifeward Announces Reverse Share Split

      Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that effective with the open of the market on Friday, March 15, 2024, the Company will complete a 1-for-7 reverse

      3/13/24 11:45:17 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care
    • ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy

      Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy. Additional study demonstrates that the improvements in walking speed and distance following high-intensity gait training with the ReStore Exo-Suit were maintained by individuals post-stroke 4 weeks after the intervention had concluded. Combined results highlight the clinical value of the ReStore Exo-Suit and its related breakthrough propulsion-augmenting technologies within the Lifeward product development pipeline. MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, M

      3/8/24 8:30:00 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lind Global Fund Ii Lp bought $40,089 worth of Ordinary Shares (54,917 units at $0.73) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      11/21/23 4:37:18 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • Lind Global Fund Ii Lp bought $49,516 worth of Ordinary Shares (72,818 units at $0.68) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      11/16/23 4:37:44 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • Lind Global Fund Ii Lp sold $3,521,840 worth of Ordinary Shares (5,031,200 units at $0.70) and bought $3,521,840 worth of Ordinary Shares (5,031,200 units at $0.70) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      9/28/23 4:30:24 PM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Financials

    Live finance-specific insights

    See more
    • Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results

      Highest quarterly and annual revenue in the history of LifewardCommercial and operational integration complete; synergiesexpected to yield $3 million in annual net savings MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced its financial results for the three months and full year ended December 31, 2023. Highlights of the Fourth Quarter of 2023 and Early 2024

      2/27/24 8:00:07 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care
    • Lifeward to Report Fourth Quarter and Fiscal Year-End 2023 Financial Results on February 27, 2024

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that the Company will release its fourth quarter and fiscal year-end 2023 financial results before the markets open on Tuesday, February 27, 2024. Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the f

      2/20/24 8:30:00 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Reports Third Quarter 2023 Financial Results

      Record Quarterly Revenue of $4.4 Million Successful Completion of AlterG Acquisition and Significant Progress of Integration Major Advancement in Efforts to Attain Medicare Payment Coverage of Exoskeletons MARLBOROUGH, Mass., BERLIN and YOKNEAM ILLIT, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced its financial results for the three and nine months ended September 30, 2023. Highlights of the Third Quarter of 2023 include: Closing of ReWalk's acquisition o

      11/14/23 8:06:13 AM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by ReWalk Robotics Ltd. (Amendment)

      SC 13D/A - ReWalk Robotics Ltd. (0001607962) (Subject)

      9/28/23 4:30:11 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by ReWalk Robotics Ltd. (Amendment)

      SC 13D/A - ReWalk Robotics Ltd. (0001607962) (Subject)

      3/9/23 4:20:24 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • SEC Form SC 13D filed by ReWalk Robotics Ltd.

      SC 13D - ReWalk Robotics Ltd. (0001607962) (Subject)

      2/22/23 5:21:58 PM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Leadership Updates

    Live Leadership Updates

    See more

    $RWLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $RWLK
    SEC Filings

    See more
    • ReWalk Robotics Appoints Michael Lawless as Chief Financial Officer

      MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 08, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) (the "Company" or "ReWalk"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced the appointment of Michael Lawless, CPA, as Chief Financial Officer, effective September 19, 2022. Mr. Lawless brings more than 20 years of experience leading finance and investor relations activities at life science and technology companies to drive greater financial discipline, better strategic decision making, and improved access to capital. "Mike brings an extensive background in strategic finance and investor relations

      9/8/22 8:30:34 AM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Confirms Receipt of Director Candidate Nominations from Creative Value Capital

      Shareholders Are Not Required to Take Action at This Time MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, May 19, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has received notice from Creative Value Capital Limited Partnership ("CVC"), which claims to hold approximately 3% of ReWalk's outstanding shares, that it intends to nominate two candidates for election to the Company's Board of Directors (the "Board") and submit two additional proposals for consideration at the 2022 Annual Meeting of Shareholders (the "Annual

      5/19/22 7:55:01 AM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Announces the Appointment of Joseph E. Turk, Jr. to their Board of Directors

      MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, April 20, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics. Ltd. (NASDAQ:RWLK) ("ReWalk" or "The Company"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, announced today that the Board has approved the appointment of Joseph Turk, Jr. to the Board of Directors, effective today. After initiating his career at McKinsey and Company, Mr. Turk has assembled an extensive history in the medical device industry beginning with his role as Director of New Business Development at Boston Scientific. Subsequently, he held multiple roles at NxStage Medical, including President, where he led all commercialization

      4/20/22 4:05:07 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • HC Wainwright reiterated coverage on ReWalk Robotics with a new price target

      HC Wainwright reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously

      3/8/21 8:24:25 AM ET
      $RWLK
      Industrial Specialties
      Health Care
    • HC Wainwright & Co. reiterated coverage on ReWalk Robotics with a new price target

      HC Wainwright & Co. reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously

      3/1/21 7:05:13 AM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ReWalk Robotics Ltd. (0001607962) (Filer)

      1/30/24 4:15:24 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Ltd. filed SEC Form 8-K: Other Events

      8-K - ReWalk Robotics Ltd. (0001607962) (Filer)

      12/19/23 4:04:05 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ReWalk Robotics Ltd. (0001607962) (Filer)

      10/13/23 4:31:13 PM ET
      $RWLK
      Industrial Specialties
      Health Care